Back to search results

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate Cancer · mCRPC (Metastatic Castration-resistant Prostate Cancer)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Fujian Cancer Hospital, Fujian, China

    Contact: Study coordinator (Yao Zhu) · zhuyao@fudan.edu.cn · 13816751347
    Contact: Principal Investigator (Yao Zhu)

  • Fudan University Shanghai Cancer Center, Shanghai, China

    Contact: Study coordinator (Yao Zhu) · zhuyao@fudan.edu.cn · 13816751347
    Contact: Principal Investigator (Yao Zhu)

  • Fudan University Shanghai Cancer Center Xiamen Branch, Xiamen, China

    Contact: Study coordinator (Yao Zhu) · zhuyao@fudan.edu.cn · 13816751347
    Contact: Principal Investigator (Yao Zhu)
View source on ClinicalTrials.gov(opens in a new tab)